Synonym
Chlorquinaldol; BRN0156683; BRN-0156683; BRN 0156683
IUPAC/Chemical Name
5,7-Dichloro-2-methyl-8-quinolinol
InChi Key
GPTXWRGISTZRIO-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H7Cl2NO/c1-5-2-3-6-7(11)4-8(12)10(14)9(6)13-5/h2-4,14H,1H3
SMILES Code
OC1=C2N=C(C)C=CC2=C(Cl)C=C1Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
228.07
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Bidossi A, Bottagisio M, De Grandi R, Drago L, De Vecchi E. Chlorquinaldol, a topical agent for skin and wound infections: anti-biofilm activity and biofilm- related antimicrobial cross-resistance. Infect Drug Resist. 2019 Jul 19;12:2177-2189. doi: 10.2147/IDR.S211007. PMID: 31410037; PMCID: PMC6650094.
2: Veraldi S, Schianchi R, Esposito L, Pontini P, Nazzaro G. Treatment of postscabies prurigo with diflucortolone and chlorquinaldol in a group of African refugees. Trop Doct. 2019 Oct;49(4):268-270. doi: 10.1177/0049475519855577. Epub 2019 Jun 18. PMID: 31208292.
3: Wang L, Deng K, Gong L, Zhou L, Sayed S, Li H, Sun Q, Su Z, Wang Z, Liu S, Zhu H, Song J, Lu D. Chlorquinaldol targets the β-catenin and T-cell factor 4 complex and exerts anti-colorectal cancer activity. Pharmacol Res. 2020 Sep;159:104955. doi: 10.1016/j.phrs.2020.104955. Epub 2020 May 30. PMID: 32485279.
4: Chen X, Guo H. Comparison of Chlorquinaldol-Promestriene Vaginal Tablets and Opin Suppositories Effect on Inflammatory Factors and Immune Function in Chronic HPV Cervicitis. J Coll Physicians Surg Pak. 2019 Feb;29(2):115-118. doi: 10.29271/jcpsp.2019.02.115. PMID: 30700347.
5: Bortolin M, Bidossi A, De Vecchi E, Avveniente M, Drago L. In vitro Antimicrobial Activity of Chlorquinaldol against Microorganisms Responsible for Skin and Soft Tissue Infections: Comparative Evaluation with Gentamicin and Fusidic Acid. Front Microbiol. 2017 Jun 8;8:1039. doi: 10.3389/fmicb.2017.01039. PMID: 28642751; PMCID: PMC5462991.
6: Agner T, Menné T. Sensitivity to clioquinol and chlorquinaldol in the quinoline mix. Contact Dermatitis. 1993 Sep;29(3):163. doi: 10.1111/j.1600-0536.1993.tb03524.x. PMID: 8222638.
7: Myatt AE, Beck MH. Contact sensitivity to chlorquinaldol. Contact Dermatitis. 1983 Nov;9(6):523. doi: 10.1111/j.1600-0536.1983.tb04485.x. PMID: 6228382.
8: Degen PH, Moppert J, Schmid K, Weirich EG. Percutaneous absorption of chlorquinaldol (Sterosan). Dermatologica. 1979;159(3):239-44. doi: 10.1159/000250600. PMID: 478062.
9: Corrihons I, Dutilh B, Bébéar C. Activité in vitro d'un antiseptique, le chlorquinaldol, sur Neisseria gonorrhoeae et Chlamydia trachomatis [In vitro activity of an antiseptic, chlorquinaldol, against Neisseria gonorrhoeae and Chlamydia trachomatis]. Pathol Biol (Paris). 1991 Feb;39(2):136-9. French. PMID: 1901985.
10: Rosanove R. Chlorquinaldol ("Steroxin") with hydrocortisone in the therapy of common dermatoses. Med J Aust. 1966 Jan 8;1(2):54-5. PMID: 5902021.
